Comparison of chiral chromatography columns for pharmaceutical method development

ANYL 409

Gregory K Webster, greg.webster@pfizer.com, Pfizer Global R & D, 2800 Plymouth Road, Ann Arbor, MI 48105
Analytical laboratories must be ready to continually address the changing nature of molecules in development in the pharmaceutical industry. In our laboratory, as well as many others, the majority of compounds screened for method development have been adequately resolved on polysaccharide based stationary phases (Diacel AD, OD, AS, and OJ) While it is hoped that this trend will continue, as new phases become available it is important to characterize their capabilities as well. After optimizing the analysis conditions for several chiral columns produced by different manufacturers, the column series were challenged by novel chemical entities developed for commercial use. The chromatographic results will be presented in comparison to the polysaccharide based phases to gauge how successful various chiral columns are in developing efficient chiral methods for current chemical entities progressing to market.